The Link Between Mean Platelet Volume to Lymphocyte Ratio and Complexity of Coronary Artery Disease

Beşli, Feyzullah; İlter, Abdulselam; Gungoren, Fatih

doi:10.1177/0003319717743315

Cited by 7 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased MPV is associated with poor prognosis in patients with acute ischemic stroke and lower lymphocyte count reduction was independently associated with an increased probability of poor function. 14 , 15 Mean platelet volume-to-lymphocyte ratio (MPVLR) has been widely used as a composite index in prognostic studies of cardiovascular disease 16 , 17 and there are few studies on cerebrovascular disease.…”

Section: Introductionmentioning

confidence: 99%

Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke

Zhai

Yang

Cao

et al. 2023

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Objective Intravenous thrombolytic therapy has become the standard of treatment for eligible patients with ischemic stroke. However, outcomes after receiving intravenous thrombolytic therapy vary widely. This study aims to investigate determinants of 1-year clinical outcomes of intravenous thrombolytic therapy for patients with acute ischemic stroke. Methods In a prospective, observational study, patients with acute ischemic stroke treated with intravenous thrombolysis were consecutively included, and clinical information and laboratory data were collected. The patients were followed up for 12 months after onset, and the 1-year clinical outcome was evaluated using modified Rankin Scale scores. A score ≥ 3 was defined as unfavorable functional outcome. Univariate and multivariate logistic regressions were used to assess the determinants of the 1-year clinical outcomes of intravenous thrombolysis for acute ischemic stroke. Results A total of 222 patients with intravenous thrombolysis were enrolled, and we identified 58 patients (26.1%) had unfavorable functional outcomes. Multivariate logistic regression analysis revealed that mean platelet volume-to-lymphocyte ratio (MPVLR) (odds ratio [OR] = 1.114, 95% confidence interval [CI]: 1.024–1.211, P = .012), atrial fibrillation (OR = 2.553, 95% CI: 1.086-6.002, P = .032), symptomatic stenosis occlusion (OR = 2.547, 95% CI: 1.269-5.110, P = .009), and baseline National Institutes of Health Stroke Scale (NIHSS) score (OR = 1.141, 95% CI: 1.074-1.212, P < .001) were independent predictors of unfavorable functional outcomes at 1 year. Conclusions In patients receiving intravenous thrombolysis, we found that MPVLR, atrial fibrillation, symptomatic stenosis occlusion, and baseline NIHSS score were significant predictors of unfavorable functional outcomes at 1 year.

show abstract

Section: Introductionmentioning

confidence: 99%

Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke

Zhai

Yang

Cao

et al. 2023

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…A number of immunocytes and blood components, such as monocytes [ 17 ], macrophages [ 18 ], dendritic cells [ 19 ], lymphocytes [ 20 ], neutrophils [ 21 ], platelets [ 22 ] and the complement system [ 23 ] contribute to the proinflammatory environment in AS, and promote the development of atherogenesis, plaque destabilization and plaque erosion. In the peripheral blood, a series of blood cellular component-related parameters, such as the neutrophil-lymphocyte ratio (NLR) [ 24 , 25 ], platelet-lymphocyte ratio (PLR) [ 26 , 27 ], monocyte-HDL ratio (MHR) [ 28 , 29 ], monocyte-lymphocyte ratio (MLR) [ 30 , 31 ] and mean platelet volume-lymphocyte ratio (MPVLR) [ 32 ], are able to illustrate systemic inflammation status and evaluate the risk of future CVD events. For example, the NLR and MLR reflect the balance between the innate (neutrophils and monocytes) and adaptive (lymphocytes) immune responses in the body [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients

Hao

et al. 2022

Atherosclerosis Plus

View full text Add to dashboard Cite

“…A number of immunocytes and blood components such as monocytes 10 , macrophages 11 , dendritic cells 12 , lymphocytes 13 , neutrophils 14 , platelets 15 and complement system 16 , have been reported to contribute to the pro-in ammatory environment in AS, promoting the development of atherogenesis, plaque destabilization and plaque erosion. A series of blood cellular component-related parameters, such as neutrophil-lymphocyte ratio (NLR) 17,18 , plateletlymphocyte ratio (PLR) 19,20 , monocyte-HDL ratio (MHR) 21,22 , monocyte-lymphocyte ratio (MLR) 23,24 and MPV-lymphocyte ratio (MPVLR) 25 have been used to illustrate systemic in ammation status and evaluate the risk of future CVD events. The treatment of hypercholesterolemia patients should focus not only on lipid lowering but also on reducing chronic in ammation 26,27 .…”

Section: Introductionmentioning

confidence: 99%

PCSK9 Inhibitor Induces a Transient Decrease in Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio in Homozygous/Compound Heterozygous Familial Hypercholesterolemia Patients

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Homozygous/compound heterozygous familial hypercholesterolemia (HoFH/cHeFH) is characterized by extremely elevated low-density lipoprotein-cholesterol (LDL-C) levels that have been reported to contribute to a long-term chronic systemic inflammation. The aims of this study are to describe the inflammatory profile of HoFH/cHeFH patients and explore the effect of PCSK9 inhibitor (PCSK9i) on a series of inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-HDL ratio (MHR), monocyte-lymphocyte ratio (MLR) and mean platelet volume-lymphocyte ratio (MPVLR). Methods: In this prospective cohort study, 21 definitive HoFH/cHeFH on high-intensity statins plus ezetimibe were placed on subcutaneous injections of PCSK9i 450mg every 4 weeks (Q4W). The biochemical parameters and inflammatory profile were analyzed at the day before PCSK9i therapy, 3 months and 6 months after PCSK9i therapy.Results: We found that HoFH/cHeFH on maximum tolerated statin dose plus ezetimibe displayed an elevated lipid and disturbed blood biomarker profile. After 3 months of add-on PCSK9i therapy, a significant reduction of LDL-C was observed. Meanwhile, percentage and count of neutrophils, monocyte counts, MPV, as well as two inflammatory biomarkers, NLR and MLR were reduced. However, at 6-month PCSK9i treatment, NLR and MLR returned to pre-PCSK9i treatment levels.Conclusions: PCSK9i induces a transient decrease in NLR and MLR in HoFH/cHeFH patients. Our results add evidence in evaluating the effects of PCSK9i on systemic inflammation.

show abstract

The Link Between Mean Platelet Volume to Lymphocyte Ratio and Complexity of Coronary Artery Disease

Cited by 7 publications

References 12 publications

Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke

Determinants of 1-Year Unfavorable Outcomes of Intravenous Alteplase Thrombolysis for Acute Ischemic Stroke

A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients

PCSK9 Inhibitor Induces a Transient Decrease in Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio in Homozygous/Compound Heterozygous Familial Hypercholesterolemia Patients

Contact Info

Product

Resources

About